Skip to main content

NXI Therapeutics AG, developer of tomorrow’s disruptive immunotherapies by coronin 1 modulation, today announces the extension of a pre-seed financing totalling to 3.5 million CHF. This financing extension comes in the run-up to a larger seed financing that the company is currently raising. Kickfund joins a group of investors including lead investor JFG Life Sciences Foundation, BaseLaunch and Venture Kick. NXI has also been supported by an InnoBooster grant from the Gebert Rüf Foundation and a Propelling grant from the University of Basel.

Further, Patrick Burgermeister, CEO of the JFG Life Sciences Foundation, will join the company’s Board of Directors. He has a highly relevant background with prior positions in venture capital (BioMedPartners), pharma (Novartis) and banking (Zürcher Kantonalbank). He holds Master’s degrees in Molecular Biology from the University of Basel and in Business Administration from the University of St. Gallen (HSG).

Read the full press release here.

Share this article

View all news

Sign up to receive our newsletter in your inbox.